- Home
- DMAC vs BANX Comparison
DMAC vs BANX Comparison
Compare DMAC & BANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- BANX
- Stock Information
- Founded
- DMAC 2000
- BANX 2013
- Country
- DMAC United States
- BANX United States
- Employees
- DMAC N/A
- BANX N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- BANX Trusts Except Educational Religious and Charitable
- Sector
- DMAC Health Care
- BANX Finance
- Exchange
- DMAC Nasdaq
- BANX Nasdaq
- Market Cap
- DMAC 178.0M
- BANX 144.3M
- IPO Year
- DMAC N/A
- BANX N/A
- Fundamental
- Price
- DMAC $3.63
- BANX $21.04
- Analyst Decision
- DMAC Strong Buy
- BANX
- Analyst Count
- DMAC 2
- BANX 0
- Target Price
- DMAC $8.00
- BANX N/A
- AVG Volume (30 Days)
- DMAC 110.0K
- BANX 21.0K
- Earning Date
- DMAC 08-06-2025
- BANX 06-17-2025
- Dividend Yield
- DMAC N/A
- BANX 9.95%
- EPS Growth
- DMAC N/A
- BANX N/A
- EPS
- DMAC N/A
- BANX 2.35
- Revenue
- DMAC N/A
- BANX $29,467,794.00
- Revenue This Year
- DMAC N/A
- BANX N/A
- Revenue Next Year
- DMAC N/A
- BANX N/A
- P/E Ratio
- DMAC N/A
- BANX $8.87
- Revenue Growth
- DMAC N/A
- BANX 2.73
- 52 Week Low
- DMAC $2.14
- BANX $17.99
- 52 Week High
- DMAC $6.82
- BANX $21.67
- Technical
- Relative Strength Index (RSI)
- DMAC 46.56
- BANX 67.44
- Support Level
- DMAC $4.02
- BANX $20.37
- Resistance Level
- DMAC $4.17
- BANX $20.96
- Average True Range (ATR)
- DMAC 0.25
- BANX 0.33
- MACD
- DMAC -0.04
- BANX 0.08
- Stochastic Oscillator
- DMAC 37.89
- BANX 85.42
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.